Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rimonabant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 known ✓ | P21554 | 8/20 | 0.96 |
| ▸ | CNR2 | P34972 | 4/20 | 0.96 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.96 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.96 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.96 |
| ▸ | MLNR | O43193 | 1/20 | 0.96 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.96 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.96 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.96 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.96 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.96 |
| ▸ | DRD1 | P21728 | 1/20 | 0.96 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.96 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.96 |
| ▸ | HRH2 | P25021 | 1/20 | 0.96 |
| ▸ | HTR2A | P28223 | 1/20 | 0.96 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.96 |
| ▸ | CCKAR | P32238 | 1/20 | 0.96 |
| ▸ | CCKBR | P32239 | 1/20 | 0.96 |
| ▸ | MC4R | P32245 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rimonabant SCHEMBL29373177 | 0.98 | CNR1 (1.00) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| Rimonabant SCHEMBL38637 | 0.98 | CNR1 (1.00) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| Rimonabant SCHEMBL1186698 | 0.97 | CNR1 (1.00) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| Rimonabant SCHEMBL29835931 | 0.97 | CNR1 (1.00) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| SCHEMBL12053639 | 0.97 | CNR1 (0.98) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| Rimonabant SCHEMBL8742390 | 0.95 | CNR1 (0.94) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| Rimonabant SCHEMBL8742211 | 0.94 | CNR1 (0.93) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| SCHEMBL14397516 | 0.94 | CNR1 (0.92) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| SCHEMBL12064382 | 0.93 | CNR1 (0.87) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| SCHEMBL29386088 | 0.93 | CNR1 (1.00) | CNR1CNR2CYP2C9GPR55ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630492-B2 | Cannabinoid derivatives | CANOPY GROWTH CORPORATION (CA) | 2026-05-19 | — | — | US | disclosed |
| US-12325709-B2 | Cannabinoid derivatives | CANOPY GROWTH CORPORATION (CA) | 2025-06-10 | — | — | US | disclosed |
| US-12252503-B2 | Cannabinoid derivatives | CANOPY GROWTH CORPORATION (CA) | 2025-03-18 | — | — | US | disclosed |
| EP-3997095-B1 | CANNABINOID DERIVATIVES | CANOPY GROWTH CORP (CA) | 2025-02-12 | — | — | EP | disclosed |
| US-12195429-B2 | Cannabinoid derivatives | CANOPY GROWTH CORPORATION (CA) | 2025-01-14 | — | — | US | disclosed |
| US-12012373-B2 | Cannabinoid derivatives | CANOPY GROWTH CORPORATION (CA) | 2024-06-18 | — | — | US | disclosed |
| US-20230134776-A1 | CANNABINOID DERIVATIVES | JGB COLLATERAL LLC | 2023-05-04 | — | — | US | disclosed |
| US-20220348586-A1 | CANNABINOID DERIVATIVES | JGB COLLATERAL LLC | 2022-11-03 | — | — | US | disclosed |
| US-20220324806-A1 | CANNABINOID DERIVATIVES | JGB COLLATERAL LLC | 2022-10-13 | — | — | US | disclosed |
| US-20220267239-A1 | CANNABINOID DERIVATIVES | JGB COLLATERAL LLC | 2022-08-25 | — | — | US | disclosed |
| US-20090042905-A1 | TRIAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | AETERNA ZENTARIS GMBH (DE) | 2009-02-12 | — | — | US | disclosed |
| WO-2009004380-A1 | METHOD AND USE OF CIRCULATING LEVELS OF ENDOCANNABINOID LIGANDS FOR THE DETERMINATION OF PATIENT IN NEED AND/OR SUITABLE FOR CB1R ANTAGONIST DRUG TREATMENT AS WELL AS METHOD FOR INDUCING WEIGHT LOSS/MAINTENANCE/GAIN | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | WO | disclosed |
| CN-101272782-A | Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors | AETERNA ZENTARIS GMBH (DE) | 2008-09-24 | — | — | CN | disclosed |
| WO-2008098977-A1 | NOVEL TRIAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | ÆTERNA ZENTARIS GMBH (DE) | 2008-08-21 | — | — | WO | disclosed |
| EP-1958631-A1 | Novel triazole derivatives as ligands of G-protein coupled receptors | AEterna Zentaris GmbH (DE) | 2008-08-20 | — | — | EP | disclosed |
| EP-1915149-A2 | NOVEL TRIAZOLE DERIVATIVES AS GHRELIN ANALOGUE LIGANDS OF GROWTH HORMONE SECRETAGOGUE RECEPTORS | AEterna Zentaris GmbH (DE) | 2008-04-30 | — | — | EP | disclosed |
| US-20070208061-A2 | NOVEL TRIAZOLE DERIVATIVES AS GHRELIN ANALOGUE LIGANDS OF GROWTH HORMONE SECRETAGOGUE RECEPTORS | ZENTARIS GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
| EP-1757290-A1 | Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors | Zentaris GmbH (DE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2007020013-A2 | NOVEL TRIAZOLE DERIVATIVES AS GHRELIN ANALOGUE LIGANDS OF GROWTH HORMONE SECRETAGOGUE RECEPTORS | ÆTERNA ZENTARIS GMBH (DE) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037857-A1 | Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors | ZENTARIS GMBH (DE) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630492-B2 | Cannabinoid derivatives | CNR2, CNR1, OPRM1 | CNR1 2/4885CNR2 1/4885CYP2C9 516/4885 |
| US-12325709-B2 | Cannabinoid derivatives | CNR1, CNR2, GPR68 | CNR1 1/4885CNR2 2/4885CYP2C9 426/4885 |
| US-20220267239-A1 | CANNABINOID DERIVATIVES | CNR2, CNR1, TRPV1 | CNR1 2/4885CNR2 1/4885CYP2C9 213/4885 |
| US-20070208061-A2 | NOVEL TRIAZOLE DERIVATIVES AS GHRELIN ANALOGUE LIGANDS OF GROWTH HORMONE SECRETAGOGUE RECEPTORS | GIPR, GHSR, GPR119 | CNR1 712/4885CNR2 1056/4885CYP2C9 4056/4885 |
| US-12252503-B2 | Cannabinoid derivatives | CNR2, CNR1, GPR18 | CNR1 2/4885CNR2 1/4885CYP2C9 231/4885 |
| US-20230134776-A1 | CANNABINOID DERIVATIVES | CNR2, CNR1, HTR2A | CNR1 2/4885CNR2 1/4885CYP2C9 619/4885 |
| US-20220348586-A1 | CANNABINOID DERIVATIVES | CNR1, CNR2, GPR68 | CNR1 1/4885CNR2 2/4885CYP2C9 426/4885 |
| US-12195429-B2 | Cannabinoid derivatives | CNR1, CNR2, OPRL1 | CNR1 1/4885CNR2 2/4885CYP2C9 278/4885 |
| US-20220324806-A1 | CANNABINOID DERIVATIVES | CNR1, CNR2, OPRL1 | CNR1 1/4885CNR2 2/4885CYP2C9 278/4885 |
| US-12012373-B2 | Cannabinoid derivatives | CNR2, CNR1, HTR2A | CNR1 2/4885CNR2 1/4885CYP2C9 619/4885 |
| US-20070037857-A1 | Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors | GIPR, GHSR, GPR119 | CNR1 712/4885CNR2 1056/4885CYP2C9 4056/4885 |
| US-20090042905-A1 | TRIAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | GPR3, GRK3, GPR88 | CNR1 62/4885CNR2 79/4885CYP2C9 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.